chartexchange

Roche’s Gazyva/Gazyvaro becomes the first FDA-approved treatment for primary membranous nephropathy

GlobeNewswire Inc. | Nov 16, 2026 1:00 AM EST

Basel, 16 November 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adult patients with primary membranous nephropathy (pMN) at risk of disease progression, to induce remission of proteinuria. Gazyva/Gazyvaro becomes the first and only therapy to receive FDA approval for this disease, having previously been granted Breakthrough Therapy Designation. A chronic autoimmune disease that can lead to kidney failure, pMN carries a substantial human and economic burden for patients, caregivers and health systems alike. 1,2 Proteinuria is a key indicator of kidney damage characterised by high urine protein levels.

Read original article